AUGTYRO

repotrectinib · E.R. Squibb & Sons, L.L.C.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for AUGTYRO, covering 2023-11-15 to 2025-01-28. Get the full timeline:

Most recent: EMA Authorised: Augtyro (repotrectinib) — Bristol-Myers Squibb Pharma EEIG